TESARO, Inc. (TSRO) Expected to Earn FY2021 Earnings of $14.60 Per Share
TESARO, Inc. (NASDAQ:TSRO) – Oppenheimer Holdings issued their FY2021 earnings per share (EPS) estimates for TESARO in a research report issued to clients and investors on Wednesday. Oppenheimer Holdings analyst L. Cann expects that the biopharmaceutical company will earn $14.60 per share for the year. Oppenheimer Holdings has a “Buy” rating and a $199.00 price target on the stock.
A number of other research analysts have also issued reports on TSRO. Gabelli initiated coverage on shares of TESARO in a research note on Friday, July 7th. They issued a “buy” rating and a $175.00 target price on the stock. Janney Montgomery Scott reiterated a “neutral” rating on shares of TESARO in a research note on Friday, July 14th. ValuEngine lowered shares of TESARO from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. BidaskClub lowered shares of TESARO from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Finally, Credit Suisse Group set a $198.00 target price on shares of TESARO and gave the company a “buy” rating in a research note on Wednesday, July 19th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $166.10.
Shares of TESARO (TSRO) traded up 0.29% during midday trading on Monday, hitting $115.95. 168,732 shares of the stock were exchanged. TESARO has a 12-month low of $106.64 and a 12-month high of $192.94. The stock’s 50 day moving average is $118.70 and its 200 day moving average is $131.65. The firm’s market cap is $6.28 billion.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. During the same quarter in the prior year, the firm earned ($1.28) EPS. The business’s quarterly revenue was down 17.6% compared to the same quarter last year.
In other news, VP Grant C. Bogle sold 14,167 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Martin H. Jr. Huber sold 592 shares of the firm’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $118.60, for a total transaction of $70,211.20. Following the transaction, the senior vice president now directly owns 6,943 shares of the company’s stock, valued at $823,439.80. The disclosure for this sale can be found here. Insiders have sold a total of 35,692 shares of company stock valued at $4,628,976 over the last ninety days. 34.60% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the company. Exane Derivatives bought a new position in TESARO during the 3rd quarter valued at about $106,000. Botty Investors LLC bought a new position in TESARO during the 2nd quarter valued at about $140,000. Nordea Investment Management AB bought a new position in TESARO during the 2nd quarter valued at about $167,000. Oppenheimer Asset Management Inc. lifted its holdings in TESARO by 3,042.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 1,430 shares during the last quarter. Finally, BB&T Securities LLC bought a new position in TESARO during the 2nd quarter valued at about $222,000.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.